
    
      The primary objective is to determine the maximum tolerated dose (MTD) of AP23573 in
      combination with doxorubicin, to characterize the safety profile of AP23573 in combination
      with doxorubicin, and to examine the pharmacokinetics of AP23573 and doxorubicin when given
      in combination to patients with advanced malignancies.
    
  